Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Generic Abuse Deterrent Opioids: FDA Offers Tier-Based Testing Approach

This article was originally published in The Pink Sheet Daily

Executive Summary

Draft guidance provides roadmap for testing generic solid oral opioid products; FDA's Califf notes difficulty in conducting post-market studies.

You may also be interested in...



Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.

Opioid Packaging Standards Could Emerge From Dosage Guidelines in Labeling

US FDA wants to work with practitioners to develop suggested prescribing standards, which could then be used to create packaging requirements.

Generic Abuse-Deterrent Opioids: Comparison To Brand Will Not Require Use Of Control

FDA final guidance recommends comparative pharmacodynamic studies for nasal and oral routes of abuse, simplifies statistical approach to show deterrence of generic is same as brand.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079250

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel